Triple-negative breast carcinoma: Heterogeneity in immunophenotypes and pharmacokinetic behavior

详细信息    查看全文

• 作者：M. Vilagran Fraguell^a ; ^{m.vilagran@tauli.cat" class="auth_mail" title="E-mail the corresponding author} ; M. Sentí ; s Crivillé ; ^a ; J. del Riego Ferrari^a ; F.J. Andreu Navarro^b ; E. Dalmau Portul&agrave ; s^c ; J. Planas Roquerols^d ; M. Lluï ; sa Baré ; ^e
• 关键词：Breast cancer ; Triple-negative phenotype ; Magnetic resonance imaging
• 刊名：Radiología (English Edition)
• 出版年：2016
• 出版时间：January-February 2016
• 年：2016
• 卷：58
• 期：1
• 页码：55-63
• 全文大小：1065 K

文摘

To evaluate the morphokinetic, pharmacokinetic, and diffusion characteristics of triple-negative breast cancers on magnetic resonance (MR) imaging and to analyze whether there is a relation between these parameters and the time to progression.

Material and methods

r0010">This was a retrospective observational study of a consecutive series of 100 patients with histologically confirmed triple-negative breast cancer studied at our center between January 2005 and December 2010. We reviewed the findings on MR locoregional extension studies, the histological findings, and the follow-up of patients until August 2014.

Results

r0015">The most common MR findings for these tumors were a rounded mass (47.3%), well-defined borders (53.7%), ring enhancement (46.2%), type 3 curves (50.5%), hyperintensity within the tumor on T2-weighted sequences, high ADC values (1.04 × 10⁻³ mm²/s), and increased capillary permeability (Kep) (0.94 min⁻¹). No significant association was observed between the morphokinetic or pharmacokinetic characteristics and the time to progression.

r0020">The in situ component in the surgical specimens was high, although its expression was low. During follow-up, 25% of patients had metastases, with a predilection for the visceral organs, and survival was low.

Conclusion

r0025">Tumors with the triple-negative phenotype mostly presented in MR as rounded tumors with well-defined borders and ring enhancement. We found no significant association between the morphokinetic or pharmacokinetic characteristics and the time to progression.